DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Funds a phase 1 or small phase 2 ALS clinical trial that must start within a year of the award, with a biomarker built in for any drug, biologic or device.
Most promising ALS treatments never get tested in people quickly enough to matter. This award pays for the trial itself, and it wants it started fast.
A trial funded here has to fit one of two focus areas. Biomarker-Driven Interventions: a disease-modifying treatment paired with a biomarker that predicts who's likely to respond and shows the treatment is engaging its target. Clinical Care: a tria…
Pilot clinical trials — phase 1 to small-scale phase 2 — for ALS, addressing either biomarker-driven disease-modifying interventions with a target-engagement biomarker or clinical-care and symptom-management interventions, starting within 12 months of award (18 for FDA-regulated studies) and building intervention-specific biomarkers into the trial design. A clinical trial is required.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up